Prelude Therapeutics Incorporated (PRLD )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PRLD
- Company Prelude Therapeutics Incorporated
- Price $2.19
- Changes Percentage 7.88
- Change 0.16
- Day Low $2.05
- Day High $2.35
- Year High $4.22
- Year Low $0.61
- Market Cap $120,853,720
- Price Avg 50 EMA (D) $2.02
- Price Avg 200 EMA (D) $1.32
- Exchange NASDAQ
- Volume 322,963
- Average Volume 981,904
- Open $2.09
- Previous Close $2.03
- EPS -1.47
- PE -1.49
- Earnings Announcement 2026-03-18 12:00:00
- Shares Outstanding $76,086,956
Company brief: PRELUDE THERAPEUTICS INCORPORATED (PRLD )
- Healthcare
- Biotechnology
- Dr. Krishna Vaddi D.V.M., Ph.D.
- https://www.preludetx.com
- US
- N/A
- 09-25-2020
- US74065P1012
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.